Organon & Co. (OGN): Free Cash Flow
$538.00M
Year ended 2025-12-31
$567.00M
Trailing 12 months to 2026-06-30
-6.7%
3-year compound annual growth
-23.3%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $538.00M | -29.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $764.00M | +39.4% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $548.00M | -17.2% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $662.00M | -66.4% | 2025-11-10, From 2022-01-01 |
| 2021-12-31 | $1.97B | -3.0% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $2.03B | -30.7% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $2.93B | n/a | 2022-03-21, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $538.00M | -29.6% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $941.74M | n/m |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $284.00M | -27.9% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.30B | -4.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $145.10M | -40.7% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.28B | -0.7% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.00B | -20.4% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $465.38M | n/m |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $724.96M | +48.7% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗